Tel:025-68136891, 17366374446  

Sign in  |  Register
中文  English
Location:Home » Education » Tutorial Introduction » Wu Junli
Wu Junli

Wu Junli is a chief physician, associate professor and master supervisor whose research direction is comprehensive treatment of pancreatic tumors. He is now the Chief Physician of General Surgery Department of the First Affiliated Hospital of Nanjing Medical University and an Associate Professor of Nanjing Medical University. He has been dedicated to the clinical, teaching and scientific research work of general surgery for 15 years and to the pancreas surgery specialty for 12 years. He participates in more than 150 various pancreatic surgeries each year and takes active part in domestic and international academic exchanges of pancreas surgery and helps to compile multiple surgical publications.

Won the First Prize of “The First Clinical Skills Competition of Chinese Medical Colleges and Universities” of the Ministry of Health in 2010 (ranked the second); won the Second Prize of “The First Clinical Skills Competition of Chinese Medical Colleges and Universities” of the Ministry of Health in 2011 (ranked the second); “The Experiment and Clinical Study of In Situ Tumor Radiofrequency Ablation” won the First Prize of 2006 Jiangsu Provincial Prize for Science and Technology (ranked the eighth); “The Serial Studies of the Dysfunction of Central Nervous System of Severe Acute Pancreatitis” won the Third Prize of 2008 Nanjing Award for Scientific and Technological Progress (ranked the fifth); “The Experiment and Clinical Study of In Situ Tumor Radiofrequency Ablation” won the Third Prize of 2009 China Award for Medical Scientific and Technological Progress (ranked the seventh); “The Foundation and Clinical Study of Pancreatic Cancer” won the Second Prize of 2012 Ministry of Education Award for Scientific and Technological Progress (ranked the tenth)

Involved in a dozen of scientific research projects as a clinical surgical doctor, including the subsidiary topics of “the National Key Support Programs of ‘the 11th Five-Year Plan’” and projects of Natural Science Foundation of China. .



1.   Wu J, Guo F, Wei J, et al. [Surgicaltreatment for pancreatic neuroendocrine neoplasmas]. Zhejiang da xue xue bao Yixue ban = Journal of Zhejiang University Medical sciences 2016; 45(1): 31-5.

2.   Wei J, Liu X, Wu J, et al. Diagnosis andsurgical management of insulinomas in 33 consecutive patients at a singleinstitution. Langenbeck's archives of surgery 2016; 401(7): 1019-25.

3.   Tu M, Lu C, Lv N, et al. Vasohibin 2 promoteshuman luminal breast cancer angiogenesis in a non-paracrine manner viatranscriptional activation of fibroblast growth factor 2. Cancer letters 2016;383(2): 272-81.

4.   Qian D, Lu Z, Jackson R, et al. Effect ofantecolic or retrocolic route of gastroenteric anastomosis on delayed gastricemptying after pancreaticoduodenectomy: A meta-analysis of randomizedcontrolled trials. Pancreatology : official journal of the InternationalAssociation of Pancreatology (IAP)  [etal] 2016; 16(1): 142-50.

5.   Lu Z, Yin J, Wei J, et al. Small amounts oftissue preserve pancreatic function: Long-term follow-up study ofmiddle-segment preserving pancreatectomy. Medicine 2016; 95(46): e5274.

6.   Huo X, Wei J, Liu X, et al. Brunner's glandcyst in combination with gastrointestinal stromal tumor: A case report.Oncology letters 2016; 11(5): 3409-12.

7.   Gao W, Dai X, Dai C, et al. Comparison ofpatency rates and clinical impact of different reconstruction methods followingportal/superior mesenteric vein resection during pancreatectomy. Pancreatology: official journal of the International Association of Pancreatology (IAP)  [et al] 2016; 16(6): 1113-23.

8.   Wei J, Liu X, Wu J, et al. Modified One-layerDuct-to-mucosa Pancreaticojejunostomy Reduces Pancreatic Fistula AfterPancreaticoduodenectomy. International surgery 2015.

9.   Wei J, Lin S, Wang C, et al. Glucagonomasyndrome: A case report. Oncology letters 2015; 10(2): 1113-6.

10. Chen J, Li Q, An Y, et al. CEACAM6 inducesepithelial-mesenchymal transition and mediates invasion and metastasis inpancreatic cancer. International journal of oncology 2013; 43(3): 877-85.

11. An Y, Cai B, Chen J, et al. MAP3K10 promotesthe proliferation and decreases the sensitivity of pancreatic cancer cells togemcitabine by upregulating Gli-1 and Gli-2. Cancer letters 2013; 329(2):228-35.

12. Zhang Y, Wei J, Wang H, et al. Epithelialmesenchymal transition correlates with CD24+CD44+ and CD133+ cells inpancreatic cancer. Oncology reports 2012; 27(5): 1599-605.

13. Wang H, Wu J, Zhang Y, et al. Transforminggrowth factor beta-induced epithelial-mesenchymal transition increases cancerstem-like cells in the PANC-1 cell line. Oncology letters 2012; 3(1): 229-33.

14. Xue X, Lu Z, Tang D, et al. Galectin-1 secretedby activated stellate cells in pancreatic ductal adenocarcinoma stroma promotesproliferation and invasion of pancreatic cancer cells: an in vitro study on themicroenvironment of pancreatic ductal adenocarcinoma. Pancreas 2011; 40(6):832-9.

15. Wu J, Wei J, Meng K, et al. Identification ofan HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.Immunopharmacology and immunotoxicology 2009; 31(3): 468-76.

16. Wei J, Gao W, Wu J, et al. Dendritic cellsexpressing a combined PADRE/MUC4-derived polyepitope DNA vaccine inducemultiple cytotoxic T-cell responses. Cancer biotherapy &radiopharmaceuticals 2008; 23(1): 121-8.